drugset / Trial / NCT06349486
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
RandomizedParallel-groupOpen-labelTreatment
Summary
1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.
Timeline
- Start
- 2023-11-28
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | 750 mg | — |
| Comparator | Amoxicillin | Other / unclassified | 1 g | — |
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Comparator | Rabeprazole | Small molecule | 20 mg | — |
| Comparator | Vonoprazan | Other / unclassified | 20 mg | — |
| Comparator | tripotassium dicitrate bismuthate | Unknown | 300 mg | — |
Indications
No indication recorded.